HK1123036A1 - Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors - Google Patents

Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Info

Publication number
HK1123036A1
HK1123036A1 HK08114022.5A HK08114022A HK1123036A1 HK 1123036 A1 HK1123036 A1 HK 1123036A1 HK 08114022 A HK08114022 A HK 08114022A HK 1123036 A1 HK1123036 A1 HK 1123036A1
Authority
HK
Hong Kong
Prior art keywords
cyclohexylamin
rho
kinase inhibitors
isoquinolone derivatives
isoquinolone
Prior art date
Application number
HK08114022.5A
Other languages
English (en)
Inventor
Oliver Plettenburg
Armin Hofmeister
Dieter Kadereit
Joachim Brendel
Matthias Loehn
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1123036A1 publication Critical patent/HK1123036A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
HK08114022.5A 2005-07-26 2008-12-29 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors HK1123036A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05016153 2005-07-26
PCT/EP2006/007140 WO2007012422A1 (en) 2005-07-26 2006-07-20 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1123036A1 true HK1123036A1 (en) 2009-06-05

Family

ID=35115842

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08114022.5A HK1123036A1 (en) 2005-07-26 2008-12-29 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Country Status (37)

Country Link
US (2) US8609691B2 (no)
EP (1) EP1912949B1 (no)
JP (1) JP5049970B2 (no)
KR (1) KR101336678B1 (no)
CN (1) CN101228132B (no)
AR (1) AR057082A1 (no)
AT (1) ATE521595T1 (no)
AU (1) AU2006274246B2 (no)
BR (1) BRPI0614063A2 (no)
CA (1) CA2615663C (no)
CR (1) CR9604A (no)
CY (1) CY1112085T1 (no)
DK (1) DK1912949T3 (no)
DO (1) DOP2006000177A (no)
EC (1) ECSP088136A (no)
ES (1) ES2372067T3 (no)
GT (1) GT200600327A (no)
HK (1) HK1123036A1 (no)
HN (1) HN2008000130A (no)
HR (1) HRP20110839T1 (no)
IL (1) IL188949A (no)
MA (1) MA29639B1 (no)
MX (1) MX2008000956A (no)
MY (1) MY146644A (no)
NI (1) NI200800024A (no)
NO (1) NO20080965L (no)
NZ (1) NZ565669A (no)
PE (1) PE20070181A1 (no)
PL (1) PL1912949T3 (no)
PT (1) PT1912949E (no)
RS (1) RS52241B (no)
RU (1) RU2440988C2 (no)
SI (1) SI1912949T1 (no)
TN (1) TNSN08038A1 (no)
TW (1) TWI412521B (no)
WO (1) WO2007012422A1 (no)
ZA (1) ZA200710952B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006008945D1 (de) 2005-06-28 2009-10-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho-kinase
NZ565669A (en) 2005-07-26 2010-05-28 Sanofi Aventis Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
NI200800025A (es) 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
US7906504B2 (en) * 2006-09-11 2011-03-15 N.V. Organon 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives
WO2008077550A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
DK2132194T3 (da) 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
CA2673917C (en) * 2006-12-27 2015-01-27 Sanofi-Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2008077552A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MY151953A (en) * 2006-12-27 2014-07-31 Sanofi Aventis Cycloalkylamine substituted isoquinoline derivatives
PL2102164T3 (pl) 2006-12-27 2011-05-31 Sanofi Aventis Pochodne izochinoliny i izochinolinonu podstawione cykloalkiloaminami
CL2008000973A1 (es) 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
WO2009054984A1 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle phenyl amide t-type calcium channel antagonists
DK2303846T3 (en) * 2008-06-24 2015-08-03 Sanofi Sa SUBSTITUTED isoquinolines AND ISOQUINOLINONER AS RHO kinase inhibitors
MX2010013974A (es) * 2008-06-24 2011-01-14 Sanofi Aventis Isoquinolinas e isoquinolinonas 6-sustituidas.
RU2532481C2 (ru) 2008-06-24 2014-11-10 Санофи-Авентис Би- и полициклические замещенные производные изохинолина и изохинолинона, полезные в качестве ингибиторов rho-киназы
JP5555236B2 (ja) * 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
EP3252049A1 (en) * 2013-01-18 2017-12-06 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
PL3290407T3 (pl) 2013-10-18 2020-09-07 Celgene Quanticel Research, Inc Inhibitory bromodomen
CN105829285A (zh) 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2016180918A1 (en) 2015-05-12 2016-11-17 Platod Combination of pharmacological and microfluidic features for improved platelets production
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017184462A1 (en) 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
JP2021527125A (ja) * 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤
CN114874236B (zh) * 2022-06-24 2023-05-05 中国工程物理研究院化工材料研究所 一种五元氮杂稠环骨架及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 選択されたハロカーボンの触媒平衡化
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ATE359822T1 (de) 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
EP1007525A1 (en) 1997-08-29 2000-06-14 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
CA2398388A1 (en) 2000-01-20 2001-07-26 Koji Kato Novel piperidine compound and pharmaceutical thereof
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (en) 2000-02-29 2001-09-07 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
EP1351936A1 (en) 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
EP1541559A4 (en) * 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
KR20050019918A (ko) * 2002-07-22 2005-03-03 아사히 가세이 파마 가부시키가이샤 5-치환 이소퀴놀린 유도체
US7615564B2 (en) 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
PT1603566E (pt) * 2003-03-11 2009-04-27 Novartis Ag Utilização de derivados de isoquinolina para tratamento de cancro e de doenças relacionadas com map-cinase
US20040225116A1 (en) 2003-05-08 2004-11-11 Payne Mark S. Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2273380B1 (en) 2003-08-22 2012-09-05 4Links Limited Communication system using embedded synchronisation
CA2539479C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
JP4969049B2 (ja) * 2004-04-06 2012-07-04 株式会社アマダ 曲げ加工装置
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1741525A1 (de) 2005-07-06 2007-01-10 Trumpf Werkzeugmaschinen GmbH + Co. KG Vorrichtung zur Aufnahme von plattenförmigen Materialien
NI200800025A (es) 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
NZ565669A (en) 2005-07-26 2010-05-28 Sanofi Aventis Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
JP4033221B2 (ja) 2005-12-02 2008-01-16 ダイキン工業株式会社 冷媒加熱装置
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
PL2102164T3 (pl) 2006-12-27 2011-05-31 Sanofi Aventis Pochodne izochinoliny i izochinolinonu podstawione cykloalkiloaminami
DK2132194T3 (da) 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer

Also Published As

Publication number Publication date
MA29639B1 (fr) 2008-07-01
GT200600327A (es) 2007-02-05
JP5049970B2 (ja) 2012-10-17
ATE521595T1 (de) 2011-09-15
NZ565669A (en) 2010-05-28
SI1912949T1 (sl) 2011-12-30
KR20080028970A (ko) 2008-04-02
IL188949A (en) 2013-11-28
ECSP088136A (es) 2008-02-20
KR101336678B1 (ko) 2013-12-04
ZA200710952B (en) 2008-11-26
US8609691B2 (en) 2013-12-17
PL1912949T3 (pl) 2012-01-31
RU2440988C2 (ru) 2012-01-27
AU2006274246B2 (en) 2012-07-12
HRP20110839T1 (hr) 2011-12-31
JP2009502830A (ja) 2009-01-29
DK1912949T3 (da) 2011-11-28
US20110251226A1 (en) 2011-10-13
CN101228132A (zh) 2008-07-23
RS52241B (en) 2012-10-31
EP1912949B1 (en) 2011-08-24
MX2008000956A (es) 2008-03-27
US8796458B2 (en) 2014-08-05
CA2615663A1 (en) 2007-02-01
TW200800906A (en) 2008-01-01
CY1112085T1 (el) 2015-11-04
ES2372067T3 (es) 2012-01-13
TNSN08038A1 (en) 2009-07-14
CN101228132B (zh) 2012-10-10
AU2006274246A1 (en) 2007-02-01
PT1912949E (pt) 2011-11-23
WO2007012422A1 (en) 2007-02-01
BRPI0614063A2 (pt) 2011-03-09
NI200800024A (es) 2009-03-03
DOP2006000177A (es) 2007-06-15
CA2615663C (en) 2013-10-15
IL188949A0 (en) 2008-04-13
AR057082A1 (es) 2007-11-14
RU2008106926A (ru) 2009-09-10
MY146644A (en) 2012-09-14
NO20080965L (no) 2008-02-22
US20080242699A1 (en) 2008-10-02
TWI412521B (zh) 2013-10-21
EP1912949A1 (en) 2008-04-23
PE20070181A1 (es) 2007-03-07
CR9604A (es) 2008-04-10
HN2008000130A (es) 2010-12-27

Similar Documents

Publication Publication Date Title
HK1123035A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
IL188949A0 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
ZA200710001B (en) Isoquinoline derivatives as inhibitors or Rho-kinase
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HK1139390A1 (en) Cycloalkylamine substituted isoquinolone derivatives
HK1105592A1 (en) Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
ZA200903554B (en) Substituted isoquinolines and their use as rho-kinase inhibitors
HK1124068A1 (en) 2-arylindole derivatives as mpges-1 inhibitors
EP1829864A4 (en) ISOCHINOLINE DERIVATIVES AS CALPAININHIBITORS
HK1112918A1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200801910B (en) Isoquinolines derivatives as IGF-IR inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160720